Skip to main content

Cardiopulmonary exercise tests in rare cardiovascular diseases

Published: 26 January 2016

A new study published on the Journal of Rare Cardiovascular Diseases highlight the importance of CPET for this kind of pathologies.

Cardiopulmonary exercise testing (CPET) is commonly used in clinical practice for both functional and diagnostic assessments of patients with cardiovascular and pulmonary disease. It provides assessment of the integrative exercise responses involving the pulmonary, cardiovascular and skeletal muscle systems, which are not adequately reflected through the measurement of individual organ system function.

The study "provide strong evidence that CPET can provide useful objective information regarding exercise tolerance and prognosis among patients after correction of congenital heart disease and pulmonary hypertension. Potential additional applications of CPET among these patients include assessment of exercise tolerance before and after therapeutic surgical and medical interventions, including exercise training programs."

The study can be downloaded for free at the following link: click here

Get in touch

COSMED strives to provide the best service possible with every contact!

Fill the online forms to get the info you're looking for right now!

Register your Product

Register your Product

Fill the online form to get software upgrades and more advantages

Read more

Request for information

Request for information

Fill the online form to get more information or a quote 

Read more

Request for Support

Request for Support

Fill the online form in order to help us fully understand your problem

Read more

COSMED LOGO
COSMED LOGO

COSMED is a world leading supplier of Cardio Pulmonary, Metabolic and Body Composition testing solutions to Sports Science, Medicine, Professional Sport and Wellness.

COSMED is a world leading supplier of Cardio Pulmonary, Metabolic and Body Composition testing solutions to Sports Science, Medicine, Professional Sport and Wellness.

FOLLOW US ON

FOLLOW US ON